Yazar "Malbora, Baris" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    COVID-19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group
    (Wiley, 2024) Bozkurt, Ceyhun; Hazar, Volkan; Malbora, Baris; Kupesiz, Alphan; Aygunes, Utku; Fisgin, Tunc; Karakukcu, Musa
    BackgroundData on the risk factors and outcomes for pediatric patients with SARS-CoV-2 infection (COVID-19) following hematopoietic stem cell transplantation (HSCT) are limited.ObjectivesThe study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID-19 infection.MethodIn this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID-19 between March 2020 and August 2022.ResultsThe median time from HSCT to COVID-19 infection was 209.0 days (IQR, 111.7-340.8; range, 0-3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID-19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p: .001) and lymphopenia at diagnosis (OR, 5.21, p: .006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p: .028), multisystem inflammatory syndrome in children (MIS-C) (OR, 31.07, p: .003), and LRTD (OR, 10.11, p: .035) were associated with a higher risk for COVID-19-related mortality.ConclusionWhile COVID-19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS-C or LRTD. COVID-19 in children following HSCT is frequently asymptomatic/mild. Nonetheless, 12% of patients have such severe disease that they need intensive care. Adverse outcomes are expected in mismatched HSCT, lymphopenia, LRTD, and MIS-C.image
  • Küçük Resim Yok
    Öğe
    The effect of chemotherapy on symptoms and nutritional status in children with cancer
    (Elsevier Sci Ltd, 2022) Gerceker, Gulcin Ozalp; Yildirim, Busra Guliz; Sulun, Ayse Aricioglu; Bektas, Murat; Ozdemir, Hamiyet Hekimci; Malbora, Baris
    Purpose: This observational study carried out to determine the incidence of poor nutritional status and symptom burden in children undergoing chemotherapy treatment. Methods: The research data collected from 187 children between the ages of 7-18 at pediatric hematology -oncology units in Izmir. The data of the study collected with Screening Tool for Risk of impaired Nutritional Status and Growth (STRONGkids), and the Memorial Symptom Assessment Scale (MSAS). Results: Patients reported a mean (SD) of 14.1 (8.1; range, 1-30) symptoms, and 43.9% were underweight. According to the STRONGkids, 62% had a high risk for malnutrition. The incidence of all symptoms increased as the Z-score of the patients worsens. There was a significant positive correlation between mean symptoms and STRONGkids malnutrition risk score, and Z-score (p < .001). Conclusion: Most of the patients were at high risk of malnutrition. It observed that chemotherapy treatment led to malnutrition. The patients with high risk for malnutrition according to the STRONGkids and severe malnutrition according to the Z-score experienced more symptoms.